Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY21 results · Jul–Sep 2020
Sun Pharma Advanced Research Company reported revenue from operations of ₹17.64 crore (up 2.6% from Q2 FY20) and net loss of ₹83.49 crore for Q2 FY21 (Jul–Sep 2020), on a standalone basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 17.64 | 17.19 | +2.6% | 185.45 | −90.5% |
| Other income | 2.82 | 2.26 | +24.8% | 0.66 | +327.3% |
| Total income | 20.46 | 19.45 | +5.2% | 186.11 | −89.0% |
| Profit before tax | (83.49) | (63.16) | Loss widened | 56.69 | Turned loss |
| Net profit for the period | (83.49) | (63.16) | Loss widened | 56.69 | Turned loss |
| EPS, basic (₹) | (3.19) | (2.41) | Loss widened | 2.16 | Turned loss |
| Net margin (%) | -473.3 | -367.4 | 30.6 |
Standalone
- Filed with BSE
- 10 Nov 2020, 19:47 IST
- Board meeting
- 09 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE